DOD Neurofibromatosis, Neurofibromatosis Research Academy Leadership Award
ID: 354666Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354666
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Neurofibromatosis Research Academy Leadership Award, aimed at enhancing research capacity in neurofibromatosis (NF). This grant opportunity seeks applications for the roles of Academy Director and Deputy Director, both of whom must be established researchers with a strong background in NF and a commitment to mentoring early-career investigators. The initiative is designed to foster innovative, high-impact research that improves understanding, diagnosis, and treatment of NF, with a total funding ceiling of $1.5 million available for this award. Interested applicants should note that the application deadline is September 12, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further inquiries.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPNFRALA_GG.pdf
    HT942524NFRPNFRALA_GG2.pdf
    The Department of Defense (DOD) is soliciting applications for the Fiscal Year 2024 Neurofibromatosis Research Academy - Leadership Award, aimed at advancing research related to neurofibromatosis (NF). This program aims to enhance the understanding, diagnosis, and treatment of NF through innovative, high-impact research focused on both clinical and translational studies. The funding opportunity has a ceiling of $1.5 million for a five-year award, with an allocation of $25 million for FY24 overall. Structured around mentorship and collaboration, the award will support two principal investigators: an Academy Director and a Deputy Director, both of whom must possess substantial experience in NF research. The agency encourages applications that align with specific critical areas, including non-tumor manifestations and health services research related to NF. Key milestones include pre-application and full application submissions, deadlines for which are outlined in the announcement. The review process involves a peer evaluation of the proposals based on leadership experience, mentorship potential, and innovative approaches to address NF challenges. This initiative illustrates a commitment to fostering future NF researchers, ultimately improving care and outcomes for individuals affected by these conditions.
    Similar Opportunities
    CDMRP Neurofibromatosis New Investigator Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis New Investigator Award to support innovative research in neurofibromatosis (NF). This grant aims to foster the development of early-stage investigators and facilitate the transition of established researchers from other fields into NF research, with a focus on enhancing understanding, diagnosis, and treatment of NF. Eligible applicants include both early-stage and established investigators, and while prior experience in NF research is not required, collaboration with experienced researchers is encouraged. The total estimated funding for this program is $2,880,000, with up to four awards expected, each allowing for direct costs not exceeding $450,000 over a maximum of three years. Interested applicants must submit a pre-application by October 3, 2024, followed by a full application, and can reach the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award, aimed at funding innovative research related to neurofibromatosis (NF). This grant supports the exploration of high-risk, high-gain concepts to enhance understanding and treatment of NF1, NF2, and schwannomatosis, with an estimated total program funding of $1.12 million and the expectation to fund approximately seven projects. The application process is two-tiered, requiring pre-applications by September 12, 2024, and full applications by October 3, 2024, with a focus on innovation, research feasibility, and impact on NF research and patient care. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Neurofibromatosis Clinical Trial Award to support innovative clinical trials aimed at addressing high-impact issues related to neurofibromatosis (NF), including NF1, NF2, and schwannomatosis. Applicants are required to present a clear clinical trial design, preliminary data, and access to suitable patient populations, with a focus on enhancing understanding, diagnosis, and treatment of NF to benefit service members, veterans, and the public. This funding opportunity, totaling approximately $1.6 million for the award, encourages collaborative proposals involving academia, industry, and military branches, with key deadlines for pre-applications on September 12, 2024, and full applications by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis Investigator-Initiated Research Program
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program (NFRP) grant to support innovative research projects focused on neurofibromatosis (NF). This program aims to enhance understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis, with a particular emphasis on improving the quality of life for affected individuals, including military personnel and veterans. The total estimated funding for this initiative is $5.36 million, with up to six awards anticipated, and applications must be submitted by October 3, 2024, following a pre-application deadline of September 12, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis Synergistic Idea Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity, is offering the Neurofibromatosis Synergistic Idea Award, a federal grant aimed at fostering collaborative research projects focused on neurofibromatosis (NF). This award encourages innovative, multidisciplinary approaches involving two or three Principal Investigators (PIs) to address significant challenges in NF research, with an emphasis on developing new therapeutics and enhancing research capacity. With an estimated total program funding of $6.4 million for FY24 and the expectation of awarding two grants, interested applicants must submit a pre-application letter of intent by September 12, 2024, followed by full applications due by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    NFRP Outreach and Invitation for Response
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    DoD Kidney Cancer, Academy of Kidney Cancer Investigators – Leadership Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is inviting applications for the FY24 Kidney Cancer Academy of Kidney Cancer Investigators – Leadership Award under the Kidney Cancer Research Program (KCRP). This funding opportunity aims to support established kidney cancer researchers at the associate professor level or higher, focusing on enhancing research capacity, fostering collaboration, and mentoring early-career investigators in kidney cancer research. With an estimated total program funding of $2.4 million, the initiative seeks to award two cooperative agreements, with applications due by September 19, 2024, following a pre-application deadline of August 29, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Kidney Cancer, Academy of Kidney Cancer Investigators - Early-Career Scholar Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Academy of Kidney Cancer Investigators - Early-Career Scholar Award, aimed at fostering innovative kidney cancer research by supporting early-career scholars. This program encourages applicants to develop research projects that address critical areas in kidney cancer biology, novel therapies, and healthcare disparities, while providing intensive mentoring and networking opportunities within a collaborative Academy environment. With an estimated total program funding of $2.32 million, the initiative anticipates awarding approximately two grants, with applications due by October 15, 2024, following a pre-application letter of intent due by September 24, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Multiple Sclerosis, Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Early Investigator Research Award (MSRP EIRA) to support innovative research focused on multiple sclerosis (MS) by early-stage investigators. This grant aims to foster the development of postdoctoral researchers with less than four years of experience, encouraging them to collaborate with experienced mentors to address critical needs in MS research, particularly in areas such as CNS repair, disease activity correlates, and MS symptomatology. The total funding available for this program is $1.6 million, with an expected five awards, each providing a maximum budget of $320,000 over two years. Key deadlines include a pre-application due by July 24, 2024, and a full application due by October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Multiple Sclerosis, Exploration - Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Multiple Sclerosis Exploration - Hypothesis Development Award (MSRP EHDA), aimed at fostering innovative research in the field of multiple sclerosis (MS). This grant program supports high-risk, high-gain research concepts that challenge existing paradigms and lay the groundwork for future scientific investigations, with a focus on areas such as central nervous system repair and mechanisms contributing to MS etiology. The total estimated funding for this program is approximately $2 million, with an expected eight awards, and applications must follow a two-step submission process, including a pre-application due by June 10, 2024, and a full application due by October 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.